26th Apr 2019 15:01
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, 26 April 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 23 April 2019, Deepa Pakianathan, a non-executive director of Mereo, received 256,734 American Depositary Shares in the Company, as set out in the following table.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Deepa Pakianathan | ||||
2 | Reason for the notification | |||||
a) | Position/status | Director | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group Plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | Mereo BioPharma Group plc American Depositary Shares ("ADSs"). Each ADS represents five ordinary shares of nominal value GBP 0.003 each in Mereo BioPharma Group Plc. ADSs - ISIN: 589492107 | ||||
b) | Nature of the transaction | Issue of ADSs in consideration for the acquisition of stock in OncoMed Pharmaceuticals, Inc. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 256,734 ADSs Aggregated price: 2,010,542 stock units in OncoMed Pharmaceuticals, Inc. | ||||
e) | Date of the transaction | 2019-04-23 | ||||
f) | Place of the transaction | Outside Trading Venue. | ||||
Related Shares:
MPH.L